Caverta (sildenafil)
Caverta is a sildenafil tablet brand attributed by the source to Ranbaxy Laboratories.
- Active ingredient
- sildenafil
- Formulation
- Oral tablet
- Company in catalogue
- Ranbaxy Laboratories Ltd
Caverta is a sildenafil tablet brand attributed by the source to Ranbaxy Laboratories. That historical company attribution is retained as a source claim; it should not be treated as the current authorization holder or manufacturing site for every market.
What distinguishes this product
The record lists 25, 50 and 100 mg tablets. Sildenafil also appears in medicines for pulmonary arterial hypertension, but that is a different prescribing context. Caverta is included here as an ED product name, without importing the source article’s pulmonary-treatment regimens into its directions.
Product record
- Record type
- Indian branded generic
- Treatment area in this directory
- Erectile dysfunction (ED)
- Active ingredient
- sildenafil
- Formulation in the cited record
- Oral tablet
- Source-listed strengths
- 25 mg, 50 mg, 100 mg
- Company in the cited record
- Ranbaxy Laboratories Ltd (Company attributed by the source catalogue)
- Manufacturing information
- A specific manufacturing site is not established by the cited catalogue record. Consult the country-specific label and pack.
- Market evidence
- Global reference; exact market authorization not established by this catalogue import
- Storage reported by source
- Store below 30°C Check the supplied leaflet for the exact presentation.
- Catalogue reviewed
Catalogue attributes describe the named product as reported by the source. Listed strengths are identification details, not dosing instructions. Ingredient evidence and company identity are useful signals; local product authorization is a separate question.
Ingredient references
These references cover the active ingredients. They do not verify every named brand, pack or formulation listed on this page.
How the ingredients fit treatment
Sildenafil supports the erection response to sexual stimulation by inhibiting PDE5. It is used before sexual activity in ED treatment; it is not a libido stimulant. Food can affect the response, so use the instructions for the prescribed presentation.
Ingredient guidance and safe use
Read the ingredient guidance alongside the leaflet for the actual product. A different brand, strength or dosage form may need different instructions.
Do not combine a PDE5 inhibitor with nitrates, recreational nitrites (“poppers”) or riociguat. Seek urgent medical help for chest pain, an erection lasting more than four hours, or sudden loss of vision or hearing. Tell the treating team which medicine you took and when.
Commonly reported effects of oral PDE5 medicines include headache, flushing, indigestion and nasal congestion; the pattern varies by ingredient and product. The cited ingredient information covers adverse effects and restrictions in more detail.
Interactions and urgent symptoms · Understanding formulations · Finding a local medicine record
Related product records
- Viagra — sildenafil
- Cenforce — sildenafil
- Cenforce Professional — sildenafil
- Cenforce-D — sildenafil + dapoxetine